M&A / Deals AstraZeneca takes another China trip, picking Dizal’s lung cancer drug for up to $1.5B BioSpaceDizal Pharmaceutical's Zegfrovy is approved in the U.S.OncologyRead full story pharminent July 14, 2026 (Last updated: July 15, 2026) BioSpace Dizal Pharmaceutical’s Zegfrovy is approved in the U.S. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Novartis and Chai Discovery collaborate on antibody identificationNext: Spero snaps up Innovent immunology drug in strategic pivot Related Stories M&A / Deals Spero snaps up Innovent immunology drug in strategic pivot pharminent July 14, 2026 M&A / Deals Novartis and Chai Discovery collaborate on antibody identification pharminent July 14, 2026 M&A / Deals Bayer banks 3bn in Apollo contraceptives division deal pharminent July 10, 2026
